Clinical trial
A Study to Evaluate the Placental Transfer of Dapirolizumab Pegol to the Infant(s) From Pregnant Study Participants With Active Systemic Lupus Erythematosus Who Are Administered Dapirolizumab Pegol
NCT07934472 is registered in ClinicalTrials.gov with UCB Biopharma SRL as lead sponsor.
Follow this trial by email Email me the PDF
Summary
Not yet recruiting, started November 2026. Interventional study, Phase 1, 25 participants (estimated). Lead sponsor UCB Biopharma SRL. Primary measures: Plasma concentration of DZP in the infants at birth; Plasma concentration of DZP in mothers at delivery and 1 more.
How it compares
267 similar trials: same condition (Lupus Erythematosus, Systemic) and phase
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Study to Evaluate the Placental Transfer of Dapirolizumab Pegol to the Infant(s) From Pregnant Study Participants With Active Systemic Lupus Erythematosus Who Are Administered Dapirolizumab Pegol
- Official title
- A Prospective, Open-Label, Single-Arm, Multicenter Pharmacokinetic Study Evaluating the Placental Transfer of Dapirolizumab Pegol to the Infant(s) From Pregnant Study Participants With Active Systemic Lupus Erythematosus Who Are Administered Dapirolizumab Pegol
- Lead sponsor
- UCB Biopharma SRL
- Phase
- Phase 1
- Overall status
- Not yet recruiting
- Start date
- November 15, 2026
- Completion date
- September 30, 2029
- Enrollment
- 25 (estimated)
- Sites
- Not reported
Conditions
MeSH condition names; the registry's own terms follow.
Registry terms: systemic lupus erythematosus
Who could take part, where it ran, who ran it
As filed in ClinicalTrials.gov.
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 45 Years
- Healthy volunteers
- No
- Study type
- Interventional
- Lead sponsor
- UCB Biopharma SRL
Arms
As registered; 1 arm.
| Arm | Type | Interventions |
|---|---|---|
| Dapirolizumab pegol (DZP) | Experimental | Dapirolizumab pegol (DZP) |
Show registry wordingPregnant women will receive DZP by intravenous (iv) administration during 2nd and 3rd trimester and after delivery they may continue for up to 1 year (if not breastfeeding). | ||
Primary endpoints
Registered primary outcome measures; 3 primary.
| Measure | Time frame |
|---|---|
| Plasma concentration of DZP in the infants at birth | At Birth during this study |
Show registry wordingPlasma concentration of DZP will be reported in infants at birth. | |
| Plasma concentration of DZP in mothers at delivery | At Delivery during this study |
Show registry wordingPlasma concentration of DZP in mothers at delivery will be reported. | |
| Ratio between plasma concentration of DZP between the infants and mother at birth/delivery | Infants: At Birth; Mothers: At Delivery during this study |
Show registry wordingRatio of plasma concentration of DZP between the infants and mother at birth/delivery will be reported. | |
Lead sponsor's other trials
UCB Biopharma SRL, most recent start first.
+124 more trials See the organization page
Similar trials
Same condition (Lupus Erythematosus, Systemic) and phase, most recent start first.
+262 more trials See the condition page